Clinical Trial Update: Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

A Phase I/II trial of the gold compound auranofin in chronic lymphocytic leukemia and related lymphoid conditions has completed its Phase 2 portion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Auranofin (Ridaura) (auranofin)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED